Article
A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 1 Feb 2022
Fanelli Giuseppe, Domschke Katharina, Minelli Alessandra, Gennarelli Massimo, Martini Paolo, Bortolomasi Marco, Maron Eduard, Squassina Alessio, Kasper Siegfried, Zohar Joseph, Souery Daniel, Montgomery Stuart, Albani Diego, Forloni Gianluigi, Ferentinos Panagiotis, Rujescu Dan, Mendlewicz Julien, De Ronchi Diana, Baune Bernhard T, Serretti Alessandro, Fabbri Chiara
Abstract excerpt
About two-thirds of patients with major depressive disorder (MDD) fail to achieve symptom remission after the initial antidepressant treatment. Despite a role of genetic factors was proven, the specific underpinnings are not fully understood yet. Polygenic risk scores (PRSs), which summarise the additive effect of multiple risk variants across the genome, might provide insights into the underlying genetics. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
